Podcast 15 Mar 2024
Reformulating psychedelics for neurodegenerative diseases
Discover how Terran Biosciences is at the forefront of revolutionizing neurological care through innovative psychedelics treatments.
Neurodegenerative disease
- Latest Posts
In Depth 4 Mar 2024
ALS: how close are we to a cure?
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.
How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases
Find out how the virtual biotech company Libra Therapeutics leveraged data to accelerate drug development for neurodegenerative diseases.
In Depth 19 Jan 2024
Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?
Check out our latest article as we explore some of the latest research around using CRISPR technology to treat neurodegenerative diseases.
Podcast 12 Jan 2024
Could natural killer cells transform Alzheimer’s treatment?
Join Dr. Paul Song, CEO of NKGen Biotech, in a podcast exploring the revolutionary use of NK cells for Alzheimer’s treatment.
In Depth 9 Nov 2023
Blood tests for Alzheimer’s: a hit or a miss?
Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 26 Oct 2023
Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials
Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […]
News and Trends 13 Jul 2023
Partnership to progress neurodegenerative disorder treatments
IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]
News and Trends 8 Jun 2023
Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients
Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD). X-ALD is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately six to eight per 100,000 live births. […]
News and Trends 27 Apr 2023
Biogen ALS drug gets FDA ok
The U.S. Food and Drug Administration (FDA) has approved Biogen’s QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients […]
In Depth 21 Apr 2023
Gut microbiome: a promising target for Parkinson’s
Home to around a thousand microbial species, the gut’s role in nutrient and drug metabolism is pivotal for immune function. As trillions of bacteria that thrive in the gastrointestinal system aid in the metabolic activity, the gut microbiome can also be influential in therapeutic research for an array of diseases, including Parkinson’s. And of late, […]
News and Trends 31 Mar 2023
€260M fund addresses dementia investment shortfall
EQT Life Sciences has closed its inaugural LSP Dementia Fund, raising approximately €260 million ($283 million) in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million ($108.9 million). The LSP Dementia Fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies […]
ADVERTISEMENT